[Form 4] Biofrontera Inc. Insider Trading Activity

Rhea-AI Filing Summary

Kevin D. Weber, a director of Biofrontera Inc. (BFRI), received a grant of employee stock options on 07/22/2025. The grant comprises 20,000 options with an exercise price of $1.00 per share and an expiration date listed as 07/22/2035. The form shows 20,000 common shares beneficially owned following the reported transaction and indicates ownership is held directly. The filer states the option "vests in twelve equal monthly installments beginning on August 22, 2025." The filing was signed on behalf of Mr. Weber by an attorney-in-fact on 09/16/2025. Other options with different terms are not included.

Positive

• Clear disclosure of grant date, option count, exercise price, expiration date, and vesting commencement
• Vesting spread across twelve monthly installments beginning 08/22/2025 aligns the director’s incentives with continued service

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine director option grant aligns executive interest with shareholders; not immediately dilutive.

The filing documents a standard equity-based compensation event: a 20,000-share employee stock option grant at a $1.00 exercise price expiring in 2035. Vesting is scheduled in twelve monthly installments starting 08/22/2025, which staggers exercisability and ties realized value to future share performance. The direct ownership shown post-grant is 20,000 shares/options. This is a typical governance tool to retain and align directors and does not itself convey operational or financial changes disclosed in the filing.

Corporate Governance Expert

TL;DR: Compensation disclosure is clear on terms and vesting schedule; represents routine director remuneration.

The Form 4 properly reports the grant date, number of options, exercise price, and stated expiration. The explicit vesting commencement date provides transparency on when economic rights begin to accrue. The form also clarifies that other option grants with different terms are excluded, limiting ambiguity. No governance concerns or unusual terms are identified from the disclosed information alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Weber Kevin Daniel

(Last) (First) (Middle)

120 PRESIDENTIAL WAY

SUITE 330

(Street)

WOBURN MA 01801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Biofrontera Inc. [ BFRI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$1	07/22/2025		A		20,000		(1)	07/22/2035	Common Stock	20,000	$0	20,000(2)	D

Explanation of Responses:

1. The option vests in twelve equal monthly installments beginning on August 22, 2025.

2. Options with different terms are not included.

	/s/ Daniel Hakansson, Attorney-in-fact for Kevin D. Weber	09/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Biofrontera (BFRI) report in this Form 4 for Kevin D. Weber?

The Form 4 reports a grant of 20,000 employee stock options to Kevin D. Weber on 07/22/2025 with an exercise price of $1.00 and an expiration date of 07/22/2035.

When do the options granted to Kevin D. Weber begin to vest?

The filing states the options vest in twelve equal monthly installments beginning on August 22, 2025.

How many shares/options does Kevin D. Weber beneficially own after the reported transaction?

The Form 4 shows 20,000 shares/options as beneficially owned following the reported transaction and indicates direct ownership.

Who signed the Form 4 for Kevin D. Weber and when?

The Form 4 was signed by Daniel Hakansson, Attorney-in-fact for Kevin D. Weber on 09/16/2025.

Are other options with different terms included in this filing?

The filing explicitly states that options with different terms are not included.